Valeant Pharmaceuticals International has concluded its exclusive worldwide collaboration agreement with GlaxoSmithKline for retigabine, an investigational drug for the treatment of adult epilepsy patients with refractory partial onset seizures. Under the terms of the agreement, Valeant received an upfront payment of $125 million from GSK.